1

Molecular Partners

#8643

Rank

$145.4M

Marketcap

CH Switzerland

Country

Molecular Partners
Leadership team

Dr. Patrick Amstutz Ph.D. (Co-Founder, CEO, Member of Management Board & Director)

Dr. Michael Tobias Stumpp Ph.D. (Co-Founder, Exec. VP of Projects & Member of Management Board)

Mr. Andreas Emmenegger E.M.B.A. (Advisor)

Products/ Services
Biotechnology, Medical, Pharmaceutical
Number of Employees
100 - 500
Headquarters
Zürich, Zurich, Switzerland
Established
2004
Company Registration
SEC CIK number: 0001745114
Net Income
100M - 500M
Revenue
100M - 500M
Traded as
MOLN
Social Media
Overview
Location
Summary
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
History

Researchers at the University of Zürich, Switzerland formed Molecular Partners AG in 2004 while studying monoclonal antibodies. These scientists discovered and developed the DARPin technology and launched the company using this platform.Molecular Partners became a publicly traded company in November 2014, when it was listed on the SIX Swiss Exchange .Since July 2021, the company is also listed on the Nasdaq in the US under the ticker symbol MOLN.

Mission
Our mission is to bring the potential of small protein drugs to the forefront of drug discovery and development, paving the way for significant therapeutic advances for a broad range of diseases.
Vision
We envision a future in which our unique and proprietary delivered to patients beyond the reach of other therapies.
Key Team

Ms. Renate Gloggner (Exec. VP of People & Community and Member of Management Board)

Mr. Alexander Zurcher (COO & Member of Management Board)

Dr. Nicolas Leupin M.B.A., Ph.D., M.D., MBA (Chief Medical Officer & Member of Management Board)

Mr. Daniel Steiner Ph.D. (Sr. VP of Research)

Mr. Seth D. Lewis (Sr. VP of Investor Relations, Communications & Strategy)

Mr. Michael Pitzner (Gen. Counsel, Compliance Officer & Sr. VP of Legal)

Mr. Thomas Schwerzmann (VP of HR)

Recognition and Awards
Molecular Partners has been recognized by the Swiss Technology Award, the Swiss Life Sciences Award, and the Prix Galien Switzerland.
References

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Molecular Partners
Leadership team

Dr. Patrick Amstutz Ph.D. (Co-Founder, CEO, Member of Management Board & Director)

Dr. Michael Tobias Stumpp Ph.D. (Co-Founder, Exec. VP of Projects & Member of Management Board)

Mr. Andreas Emmenegger E.M.B.A. (Advisor)

Products/ Services
Biotechnology, Medical, Pharmaceutical
Number of Employees
100 - 500
Headquarters
Zürich, Zurich, Switzerland
Established
2004
Company Registration
SEC CIK number: 0001745114
Net Income
100M - 500M
Revenue
100M - 500M
Traded as
MOLN
Social Media